Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
13h
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...
GlobalData on MSN17h
Alector stock drops after Alzheimer’s drug fails in Phase II trial"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Jeffrey Hung has given his Sell rating due to a combination of factors, primarily driven by the unfavorable ...
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback